Restart Life Sciences Corp (OP:NMLSF)

0.0822 UNCHANGED

Streaming Delayed Price Updated: 1:32 PM EST, Feb 5, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	0.0822
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0822
Today's Range	0.0822 - 0.0822
52wk Range	0.0300 - 0.0950
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism ↗

April 20, 2023

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

Via Benzinga

Performance

YTD	+0.6%	+0.6%
1 Month	+0.6%	+0.6%
3 Month	+46.8%	+46.8%
6 Month	+21.1%	+21.1%
1 Year	+2.7%	+2.7%

More News

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Via Benzinga

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder ↗

February 14, 2023

Via Benzinga

Nova Mentis Is Looking To Treat Autism With Psilocybin ↗

April 07, 2022

Via Benzinga

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval ↗

December 27, 2022

Via Benzinga

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗

December 06, 2022

Via Benzinga

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial ↗

November 30, 2022

Via Benzinga

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial ↗

November 17, 2022

Via Benzinga

Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin ↗

September 30, 2022

Via Benzinga

Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn ↗

September 29, 2022

Via Benzinga

Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application

September 29, 2022

Via Newsfile

New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details ↗

September 17, 2022

Via Benzinga

Nova Mentis Completes Production of Psilocybin Microdose Capsules

September 15, 2022

Via Newsfile

More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases ↗

June 16, 2022

Via Benzinga

Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies ↗

June 08, 2022

Via Benzinga

Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened ↗

June 07, 2022

Via Benzinga

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study ↗

February 22, 2022

Via Benzinga

This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism ↗

February 16, 2022

Via Benzinga

Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market ↗

February 08, 2022

Via Benzinga

Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis ↗

January 27, 2022

Via Benzinga

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗

November 08, 2021

Via Benzinga

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗

October 26, 2021

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Via Benzinga

Frequently Asked Questions

Is Restart Life Sciences Corp publicly traded?

Yes, Restart Life Sciences Corp is publicly traded.

What exchange does Restart Life Sciences Corp trade on?

Restart Life Sciences Corp trades on the OTC Traded

What is the ticker symbol for Restart Life Sciences Corp?

The ticker symbol for Restart Life Sciences Corp is NMLSF on the OTC Traded

What is the current price of Restart Life Sciences Corp?

The current price of Restart Life Sciences Corp is 0.0822

When was Restart Life Sciences Corp last traded?

The last trade of Restart Life Sciences Corp was at 02/05/26 01:32 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.